WO2008122670A3 - Human diabetes susceptibility tnfrsf10b gene - Google Patents

Human diabetes susceptibility tnfrsf10b gene Download PDF

Info

Publication number
WO2008122670A3
WO2008122670A3 PCT/EP2008/054374 EP2008054374W WO2008122670A3 WO 2008122670 A3 WO2008122670 A3 WO 2008122670A3 EP 2008054374 W EP2008054374 W EP 2008054374W WO 2008122670 A3 WO2008122670 A3 WO 2008122670A3
Authority
WO
WIPO (PCT)
Prior art keywords
human diabetes
diabetes susceptibility
tnfrsf10b gene
tnfrsf10b
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/054374
Other languages
French (fr)
Other versions
WO2008122670A2 (en
Inventor
Anne Philippi
Joerg Hager
Francis Rousseau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IntegraGen SA
Original Assignee
IntegraGen SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IntegraGen SA filed Critical IntegraGen SA
Priority to EP08736091A priority Critical patent/EP2134866A2/en
Priority to US12/593,060 priority patent/US20110129820A1/en
Priority to CA002682538A priority patent/CA2682538A1/en
Publication of WO2008122670A2 publication Critical patent/WO2008122670A2/en
Publication of WO2008122670A3 publication Critical patent/WO2008122670A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a diagnostic method of determining whether a subject is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the TNFRSF10B gene locus in a biological sample of said subject.
PCT/EP2008/054374 2007-04-10 2008-04-10 Human diabetes susceptibility tnfrsf10b gene Ceased WO2008122670A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08736091A EP2134866A2 (en) 2007-04-10 2008-04-10 Human diabetes susceptibility tnfrsf10b gene
US12/593,060 US20110129820A1 (en) 2007-04-10 2008-04-10 Human diabetes susceptibility tnfrsf10b gene
CA002682538A CA2682538A1 (en) 2007-04-10 2008-04-10 Human diabetes susceptibility tnfrsf10b gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91083507P 2007-04-10 2007-04-10
US60/910,835 2007-04-10

Publications (2)

Publication Number Publication Date
WO2008122670A2 WO2008122670A2 (en) 2008-10-16
WO2008122670A3 true WO2008122670A3 (en) 2008-12-11

Family

ID=39714106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/054374 Ceased WO2008122670A2 (en) 2007-04-10 2008-04-10 Human diabetes susceptibility tnfrsf10b gene

Country Status (4)

Country Link
US (1) US20110129820A1 (en)
EP (1) EP2134866A2 (en)
CA (1) CA2682538A1 (en)
WO (1) WO2008122670A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ610356A (en) 2008-08-28 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2735590A1 (en) 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ607703A (en) 2008-10-21 2014-09-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102264230B (en) 2008-11-10 2014-12-10 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2770393A1 (en) 2009-08-07 2011-02-10 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ598712A (en) * 2009-08-28 2014-05-30 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2496942B1 (en) 2009-11-07 2017-03-22 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5763098B2 (en) 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド Methods and compositions for diagnosis and prognosis of renal injury and renal failure
PT2666872T (en) 2010-02-05 2016-07-08 Astute Medical Inc PROCESSES AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF RENAL INJURIES AND RENAL INSUFFICIENCY
EP3070474A3 (en) 2010-02-26 2016-12-07 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
IN2012MN02812A (en) 2010-06-23 2015-05-22 Astute Medical Inc
ES2734494T3 (en) 2011-12-08 2019-12-10 Astute Medical Inc Methods and uses for the diagnosis of kidney injury and kidney failure
TR201807542T4 (en) 2013-01-17 2018-06-21 Astute Medical Inc Methods and compositions for the diagnosis and prognosis of renal injury and renal failure.
EP3465201A4 (en) 2016-06-06 2020-08-26 Astute Medical, Inc. MANAGEMENT OF ACUTE RENAL INJURY WITH INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE INHIBITORS OF METALOPROTEINASE 2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006022629A1 (en) * 2004-07-22 2006-03-02 Sequenom, Inc. Methods of identifying risk of type ii diabetes and treatments thereof
WO2006063703A2 (en) * 2004-12-13 2006-06-22 F.Hoffmann-La Roche Ag Single nucleotide polymorphism (snp) associated to type ii diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006022629A1 (en) * 2004-07-22 2006-03-02 Sequenom, Inc. Methods of identifying risk of type ii diabetes and treatments thereof
WO2006063703A2 (en) * 2004-12-13 2006-06-22 F.Hoffmann-La Roche Ag Single nucleotide polymorphism (snp) associated to type ii diabetes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRAYLING TIMOTHY M ET AL: "Young-onset type 2 diabetes families are the major contributors to genetic loci in the Diabetes UK Warren 2 genome scan and identify putative novel loci on chromosomes 8q21, 21q22, and 22q11.", DIABETES JUL 2003, vol. 52, no. 7, July 2003 (2003-07-01), pages 1857 - 1863, XP007905580, ISSN: 0012-1797 *
MORITANI M ET AL: "Genetic association of single nucleotide polymorphisms in endonuclease G-like 1 gene with type 2 diabetes in a Japanese population", DIABETOLOGIA ; CLINICAL AND EXPERIMENTAL DIABETES AND METABOLISM, SPRINGER, BERLIN, DE, vol. 50, no. 6, 6 April 2007 (2007-04-06), pages 1218 - 1227, XP019510576, ISSN: 1432-0428 *

Also Published As

Publication number Publication date
CA2682538A1 (en) 2008-10-16
WO2008122670A2 (en) 2008-10-16
EP2134866A2 (en) 2009-12-23
US20110129820A1 (en) 2011-06-02

Similar Documents

Publication Publication Date Title
WO2008122670A3 (en) Human diabetes susceptibility tnfrsf10b gene
WO2010053587A3 (en) Methods of monitoring conditions by sequence analysis
WO2006128192A3 (en) Use of free circulating dna for diagnosis, prognosis, and treatment of cancer
WO2005114190A3 (en) Methods of identifying biomarkers
WO2007103808A3 (en) Microrna expression profile associated with pancreatic cancer
GB0603251D0 (en) DNA conformation
WO2012018535A3 (en) Wellness panel
WO2009077864A3 (en) Compositions and methods of detecting tiabs
WO2011064225A8 (en) Novel diagnostic method for the diagnosis of alzheimer's disease or mild cognitive impairment
WO2013071119A3 (en) Methods for treating, diagnosing and monitoring alzheimer's disease
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
WO2008008284A3 (en) Cancer biomarkers and methods of use threof
WO2007114986A3 (en) Cooperative probes and methods of using them
WO2010025393A3 (en) Protein biomarkers and methods for diagnosing kawasaki disease
WO2007098444A3 (en) Methods for analysis of extracellular rna species
WO2008012650A3 (en) An immunochromatography device for the diagnosis of diseases in a sample
WO2009001545A1 (en) Method for detection or treatment of graft versus host disease
WO2010132447A3 (en) Methods for detecting pre-diabetes and diabetes using differential protein glycosylation
WO2010092164A3 (en) Bacterial dna as markers of cardiovascular and/or metabolic disease
WO2010047938A3 (en) Mmp activation peptide detection in biological samples
WO2009007649A3 (en) Device and method for identifying and determining blood groups
WO2009042680A3 (en) Detection of mutations in acta2 and myh11 for assessing risk of vascular disease
WO2010144553A3 (en) Methods for diagnosing blood vessel reocclusion
WO2011109112A3 (en) Method of detecting tau protein and tau fragments in serum
WO2008138928A3 (en) Diagnostic of immune graft tolerance

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08736091

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008736091

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12593060

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2682538

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE